Bee Venom Therapies from Basic Science to Clinical Fields
This special issue belongs to the section "Animal Venoms".
Special Issue Information
Dear Colleagues,
Bee toxin has historically been used for various pain conditions such as arthritis, rheumatoid diseases, and musculoskeletal pain for therapeutic purposes in many countries. Bee venom contains many bioactive compounds which exert pharmacological effects presenting analgesic, anti-inflammatory, anti-cancer, and immune-stimulant effects. There were several systematic reviews on the effectiveness and safety of bee venom therapy in the treatment of rheumatoid arthritis, musculoskeletal pain, shoulder pain, and post-stroke shoulder pain. This means bee venom has been used towards therapeutic aims and clinical trials, especially randomized controlled trials, which have been conducted in the effort of determining the effectiveness and safety of bee venom in clinical fields.
However, many concerns should be addressed with regard to bee venom use in the clinical field. How should it be standardized for therapeutic dosage and how can this be used with good safety? What is the mechanism of the effects of bee venom and its compounds? How can we maximize its positive effects?
This Special Issue will focus on the clinical use of bee venom and bee venom acupuncture in the clinical field, but not limited to clinical trials. This includes basic research such as animal experimental studies (in vivo and in vitro), ingredients, surveys on its use, as well as reviews and systematic reviews.
Dr. Byung-Cheul Shin
Dr. Soo-Hyun Sung
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- bee venom
- bee toxin
- bee venom acupuncture
- randomized clinical trial
- systematic review
- melittin
- adolapin
- apamin
- Phospholipase A2
- safety
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

